Replication analysis of the Coronavirus Anxiety Scale

Sherman A. Lee

1Christopher Newport University, Department of Psychology, Newport News, Virginia - USA

ABSTRACT
As fear and anxiety rates increase during the COVID-19 crisis, the need to study and screen and treat vulnerable populations is vitally important. Accordingly, the Coronavirus Anxiety Scale, a mental health screener of coronaphobia, has been created to aid this effort. The results of a replication analysis reported here support the diagnostic and psychometric properties of this pandemic-related mental health screener. Considerations of this scale’s use are also discussed.

Keywords: Anxiety, coronaphobia, coronavirus, CAS, COVID-19

INTRODUCTION
As the COVID-19 crisis continues to upend the global economy and everyday life, many people live with fear and anxiety. Frontline workers, like medical staff, are particularly vulnerable because they work in dangerous situations and are often isolated from their families and sources of support (1). Because this pandemic-related anxiety has been shown to correlate strongly with depression, generalized anxiety, and suicidal ideation (2), it is important that health professionals appropriately and efficiently screen and treat these at-risk individuals (3).

To aid in this process, I created a mental health screener of clinical anxiety (Corona Anxiety Scale [CAS]; see Table 1) related to the coronavirus crisis, otherwise known as "coronaphobia" (4), that has quickly gained international use among researchers and health professionals (5). Although this instrument demonstrated strong psychometric and diagnostic qualities in the original CAS investigation, these findings have not been verified on an independent sample. To ensure that the CAS truly embodies qualities worthy of a widely used mental health screener, replication analyses on this scale need to be conducted and the results should be peer-reviewed.

To address this essential concern, I examined unanalyzed data from a study recently published in the journal Psychological Medicine that focused on the mental health characteristics of people with coronaphobia (2). I chose this dataset because the sample size is sufficiently large (n=1237) and demographically similar to the U.S. population (72.6% White; 54.6% male). This replication analysis consisted of a bootstrap (2000 samples) ML confirmatory factor analysis (CFA) on the items of the CAS and a receiver operating characteristic curve (ROC) analysis on the CAS total scores using the Work and Social Adjustment Scale as the criterion measure of functional impairment (6).

METHOD
Participants and Procedure
The study sample consisted of 675 men, 558 women, and 4 “other” with a combined mean age of 38.09 (SD=12.32) years. Most of the participants were White
(n=898; 71.9%), followed by Black (n=129; 10.4%), Asian (n=106; 9.6%), Hispanic (n=85; 6.9%), and “other” (n=19; 1.5%). The majority of the participants had a Bachelor’s degree or higher (n=715; 57.8%) and had not been diagnosed with the coronavirus (n=1117; 95.1%).

The research for this study was approved by the institutional review board of Christopher Newport University (USA). The participants were recruited on April 2, 2020, through Amazon MTurk in exchange for payment (US $ 0.50) and were eligible if they provided consent and information that was valid and complete. Data were collected using Survey Monkey software and analyzed using IBM SPSS version 26 and IBM AMOS version 25.

**Measures**

*Work and Social Adjustment Scale (WSAS)*: The WSAS was used to measure functional impairment due to the coronavirus outbreak (6). Participants were asked to rate five items of the WSAS, using a 9-point severity scale (0=“not at all” to 8=“very severely”), regarding how much impairment they experienced because of the coronavirus outbreak. Based on a WSAS cut score of ≥21, 35.0% of the sample was classified as functionally impaired. Cronbach’s α was 0.78.

*Coronavirus Anxiety Scale (CAS)*: The CAS was used to measure coronaphobia (5). Participants were asked to rate five items of the CAS, using a 5-point frequency scale (0=“not at all” to 4=“nearly every day over the last 2 weeks”), regarding how often they experienced physiologically-based symptoms of fear or anxiety when exposed to coronavirus-related thoughts or information. Based on a CAS cut score of ≥9, 25.4% of the sample was classified as dysfunctionally anxious. Cronbach’s α was 0.92.

**Results**

The results of the CFA demonstrated that the CAS is a highly reliable (α=0.92) and factorially valid measure ($\chi^2 [5]=25.12, p<0.001$) that meets conventional standards for model fit (CFI=1.00; TLI=0.99; SRMR=0.01; RMSEA=0.06 [90% CI 0.04, 0.08]) (7). The results of the ROC analysis also confirmed that the CAS has solid discrimination ability, as determined by a convex pattern on a ROC graph and an AUC value of 0.80 (p<0.001), as well as a strong specificity rate of 89%. However, the CAS cut score ≥9 yielded a sensitivity of 53% for this sample, which was well below the 90% value reported in the original CAS investigation. The CAS cut score had to be lowered to ≥5 in order for the sensitivity rate to be acceptable at 71%. Although this cut score reduced the specificity rate to 74%, the diagnostic values were still within acceptable ranges for mental health screening.

**Discussion**

Taken together, the results of this replication analysis support the CAS as a psychometrically sound mental health screener with acceptable classification features.
The one aspect of the CAS that did not replicate was its ability to detect individuals who were functionally impaired by their coronavirus anxiety. The original cut score of ≥9 appeared to be too stringent for this sample and had to be lowered to ≥5 in order for the CAS to have a reasonable sensitivity rate. This discrepancy may reflect the differences in the samples. The original CAS investigation was exclusively composed of people with anxiety about the coronavirus, while the sample used in this analysis included people with and without anxiety because this particular study did not have an anxiety prerequisite. Although future research should clarify the source of this unexpected finding, current users of the CAS may consider lowering the cut score to ≥5 when assessing the general population, but retaining the cut score of ≥9 when screening at-risk or anxious groups.

Future research should also consider the appropriate adaptation of the CAS for populations outside of the U.S. On the Coronavirus Anxiety Project website (8), an online site for resources on coronaphobia, there are twenty translated versions of the CAS (as of June 30, 2020), including one in Turkish by Dr. Cuneyt Evren. Although these translated versions are important for the assessment and study of coronaphobia, it is crucial that psychometric studies be conducted before they are adopted for clinical and scholarly use. Specifically, these adapted versions of the CAS should meet rigorous standards of reliability and validity, as demonstrated by the Turkish version (9), and be culturally sensitive, as well (10).

<table>
<thead>
<tr>
<th>Contribution Categories</th>
<th>Author Initials</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category 1</td>
<td>S.A.L.</td>
</tr>
<tr>
<td>Concept/Design</td>
<td></td>
</tr>
<tr>
<td>Data acquisition</td>
<td></td>
</tr>
<tr>
<td>Data analysis/interpretation</td>
<td></td>
</tr>
<tr>
<td>Category 2</td>
<td>S.A.L.</td>
</tr>
<tr>
<td>Drafting manuscript</td>
<td></td>
</tr>
<tr>
<td>Critical revision of manuscript</td>
<td></td>
</tr>
<tr>
<td>Category 3</td>
<td>S.A.L.</td>
</tr>
<tr>
<td>Final approval and accountability</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>S.A.L.</td>
</tr>
<tr>
<td>Technical or material support</td>
<td></td>
</tr>
<tr>
<td>Supervision</td>
<td>N/A</td>
</tr>
</tbody>
</table>

**Ethics Committee Approval:** The research for this study was approved by the institutional review board of Christopher Newport University (USA).

**Informed Consent:** Written informed consent of all patients was obtained.

**Peer-review:** Externally peer-reviewed.

**Conflict of Interest:** None declared.

**Financial Disclosure:** No funding received for research.

**REFERENCES**